Dr. Eugene Pashkovetsky, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 1,543
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
NY license 281254 -
Advanced Heart Failure and Transplant Cardiology Physician
NY license 281254
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Albany Medical Center Hospital Albany, NY
- St Peter's Hospital Albany, NY
- Samaritan Hospital of Troy, New York Troy, NY
- Columbia Memorial Hospital Hudson, NY
- Aurelia Osborn Fox Memorial Hospital Oneonta, NY
Medical groups
- Capital Cardiology Associates PLLC (73 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,543
- Services billed
- 9,870
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 779 | 630 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 665 | 386 |
| Injection, regadenoson, 0.1 mg | 472 | 118 |
| Established patient office or other outpatient visit, 30-39 minutes | 460 | 287 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 296 | 226 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 277 | 265 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 262 | 184 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 210 | 105 |
| Insertion of needle into vein for collection of blood sample | 197 | 150 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 194 | 190 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 95 payments worth $3,314 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $1,496 |
|---|---|
| Aop Health US, LLC | $326 |
| AstraZeneca Pharmaceuticals LP | $298 |
| Novartis Pharmaceuticals Corporation | $236 |
| Alnylam Pharmaceuticals Inc. | $185 |
| Pfizer Inc. | $127 |
| Merck Sharp & Dohme LLC | $118 |
| Bridgebio Pharma, Inc. | $102 |
| Food and Beverage | $1,964 |
|---|---|
| Consulting Fee | $1,350 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Jan 21, 2025 | Consulting Fee | $1,350 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $25,392 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF)
E.r. Squibb & Sons, L.l.c. - Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06122779
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.